Qilian International Holding Group Limited - Asset Resilience Ratio

Latest as of September 2025: 0.23%

Qilian International Holding Group Limited (BGM) has an Asset Resilience Ratio of 0.23% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Qilian International Holding Group Limit short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$994.89K
Cash + Short-term Investments

Total Assets

$433.81 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Qilian International Holding Group Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Qilian International Holding Group Limit's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Qilian International Holding Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BGM long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $994.89K 0.23%
Total Liquid Assets $994.89K 0.23%

Asset Resilience Insights

  • Limited Liquidity: Qilian International Holding Group Limited maintains only 0.23% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Qilian International Holding Group Limited Industry Peers by Asset Resilience Ratio

Compare Qilian International Holding Group Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.48%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
Drug Manufacturers - Specialty & Generic 1.01%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%

Annual Asset Resilience Ratio for Qilian International Holding Group Limited (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Qilian International Holding Group Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-09-30 0.23% $994.89K $433.81 Million -15.47pp
2024-09-30 15.70% $8.32 Million $53.00 Million -13.45pp
2023-09-30 29.15% $14.94 Million $51.26 Million --
2022-09-30 0.00% $0.00 $64.53 Million --
2019-09-30 0.00% $0.00 $35.27 Million --
2018-09-30 0.04% $14.58K $33.34 Million --
pp = percentage points

About Qilian International Holding Group Limited

NASDAQ:BGM USA Drug Manufacturers - Specialty & Generic
Market Cap
$98.58 Million
Market Cap Rank
#19335 Global
#4435 in USA
Share Price
$0.26
Change (1 day)
+0.43%
52-Week Range
$0.25 - $11.75
All Time High
$58.32
About

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufactu… Read more